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Abstract
Background: Myoepithelial carcinoma is a rare tumour. The clinical and biological behaviours of these tumours are
variable. Although many factors have been evaluated as potential prognostic indicators, including clinical stage, site
and size of the tumour, high proliferative activity, extensive invasion into the surrounding tissue, perineural
permeation, the abnormal presence of nuclear DNA content, and marked cellular pleomorphism, there are no
definite histological features that clearly correlate with their behaviour. Thus, conclusions regarding prognostic
factors and ideal treatment may emerge as the number of investigated myoepithelial carcinoma cases accumulate.
Methods: Using immunohistochemistry, expression levels of p63 and Ki-67 were determined in 16 myoepithelial
carcinoma samples and correlated with clinicopathological characteristics and patient prognosis.
Results: p63 expression was detected in six of the myoepithelial carcinoma tissues (37.5%) and Ki-67 was detected
in five (31.3%). In addition, p63 and Ki-67 expression levels were associated with myoepithelial carcinoma
recurrence and metastasis. All six patients with p63-positive expression died due to disease or cardiovascular
disease (mean survival time = 50.5 months), and p63 expression was statistically significant with respect to survival
(P = 0.01). Four patients with Ki-67-positive expression died due to disease or cardiovascular disease (mean survival
time = 44.0 months); however, there was no statistically significant difference between Ki-67 expression and
survival (P = 0.24).
Conclusions: Recurrence and metastasis in myoepithelial carcinomas are more frequent in p63-positive and Ki-67-
positive EMCs, and poor prognosis is associated with overexpression of p63.
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Background
Myoepithelial carcinoma (MEC) is a rare tumour that
was first described by Stromayer et al. (1975) [1]. MEC
consists of atypical myoepithelial cells with high mitotic
activity and aggressive growth [2]. MEC is an extremely
rare tumour of the minor salivary glands, accounting for
less than 1% of tumours of this origin [3]. An English-
limited PubMed search revealed fewer than 300 cases of
MME, with most reports being single case studies [2-7].
The clinical and biological behaviours of these tumours
are variable. Although many factors have been evaluated
as potential prognostic indicators, including clinical
stage, site and size of the tumour, high proliferative
activity, extensive invasion into the surrounding tissue,
perineural permeation, the abnormal presence of nuclear
DNA content, and marked cellular pleomorphism [5],
there are no definite histological features that clearly
correlate with their behaviour [3]. Thus, conclusions
regarding prognostic factors and ideal treatment may
emerge as the number of investigated MEC cases
accumulate.
p63 is a p53-related DNA-binding protein that helps
regulate differentiation and proliferation in epithelial
progenitor cells [8]. Recently, p63 was identified as a
novel myoepithelial marker that is variably expressed in
MECs [7]. The prognostic value of p63 expression in
malignant tumours is controversial. Some studies have
shown that p63 expression is a good prognostic marker
for patients with human urothelial carcinoma [9], but is
not an independent prognostic factor for overall survival
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other reports have found that p63-positive cases had a
worse prognosis in patients with oral squamous cell car-
cinoma [11], adenoid cystic carcinoma of the salivary
gland [12], and Merkel cell carcinoma [13]. There are
scant data on the association between p63 expression
and the prognosis of MEC.
Ki-67 is another marker of cell proliferation [14] and
its prognostic significance has been reported in various
tumours, including laryngeal carcinoma [15], salivary
gland adenoid cystic carcinoma [16], mucoepidermoid
carcinoma [17], hepatocellular carcinoma [18], breast
carcinoma [19], and lung carcinoma [20]. However, ele-
vated Ki-67 expression in oral and oropharyngeal squa-
mous cell carcinoma did not predict the prognosis of
carcinoma [21].
The aims of this study were to determine the expres-
sion levels of P63 and Ki-67 in MECs and to establish if
the expression of either marker was predictive of
survival.
Methods
Patient and tissue samples
MEC cases were sourced from the surgical pathological
files of patients treated at Zhejiang Cancer Hospital
between 1998 and 2010. The archived tissues obtained
from the institutional and consultation files were forma-
lin-fixed and paraffin-embedded. One representative
paraffin block from each tumour was selected for immu-
nohistochemical study. Approval for the study was
obtained through the Zhejiang Cancer Hospital Institu-
tional Review Board.
Follow-up information on the patients’ clinical out-
come was gathered, including type of treatment, dura-
tion of survival following first treatment, tumour
recurrence and metastasis, follow-up treatment, time
between first treatment and death, and cause of death.
Immunohistochemistry
Immunohistochemistry analyses were performed to
assess the expression of cytokeratin (CK), alpha-smooth
muscle actin (a-SMA), vimentin, S-100 protein, calpo-
nin, glial fibrillary acidic protein (GFAP), p63, and Ki-67
in the tissue samples. Dilutions and suppliers for all pri-
mary antibodies used in the study are detailed in
Table 1. Primary antibodies against the respective pro-
teins were added and incubated overnight at 4°C in a
humidified chamber. After rinsing with phosphate buf-
fered saline (PBS), slides were incubated with secondary
antibody followed by streptavidin-biotin-peroxidase
complex, both for 30 min at room temperature with a
PBS wash between each step on a Lab Vision Autostai-
ner 720 (Thermo Fisher Scientific, CA, USA) according
to the manufacturer’s instructions. All tissue slides were
counterstained using haematoxylin and eosin (H&E)
staining. Appropriate negative and positive controls
were used for each antibody throughout the study, with
negative controls omitting the primary antibody. Two
pathologists, who were blinded to the clinical outcome
and other clinical data, independently evaluated the
immunohistochemical studies of p63 and Ki-67. The
percentage of neoplastic cells with nuclear staining was
calculated. A tumour was considered positive when
greater than 10% of the neoplastic cells unequivocally
expressed p63 or Ki-67 in the nuclei and negative when
less than 10% of the malignant cells stained for p63 or
Ki-67.
Statistical analysis
The correlation between immunohistochemical data and
clinicopathological features was examined using Fisher’s
exact test, with a P-value of < 0.05 considered to be sta-
tistically significant. The survival rate was calculated by
the Kaplan-Meier method, and statistical differences
were assessed by the log-rank test using the SPSS WIN
program package 16.0 (SPSS, Inc., Chicago, IL, USA).
Results and discussion
Patients and clinical features
Tissue samples from 16 cases of MECs were used in this
study. The cases comprised 10 men and 4 women, ages
22-80 years (mean 49.3 years) (Table 2). Tumours arose
from the parotid gland (n =4 ) ,l u n g( n = 3), maxillary
sinus (n = 2), nasal cavity (n =2 ) ,b r e a s t( n =2 ) ,s u b -
mandibular gland (n =1 ) ,l a r y n x( n = 1), and palate
(n = 1) (Table 2). Follow-up information was sought for
all patients, with the duration of follow-up ranging from
12 to 72 months (mean 36.3 months) (Table 2). Seven
patients with complete follow-up had no evidence of
recurrence, including two patients with recurrent disease
who were treated with additional surgery. Five patients
had local recurrences and distant metastases. Sites of
metastases included the lung, liver, and brain. Seven
patients died of their disease at last follow-up and one
Table 1 Antibodies and Dilutions Used in
Immunohistochemical Staining
Antibody Dilution Company
CK14 1:125 Dako, Carpinteria, CA, USA
a-SMA 1:5000 Sigma BioSciences, St Louis, MO, USA
Des 1:100 Dako, Carpinteria, CA, USA
Vim 1:100 Dako, Carpinteria, CA, USA
S-100 1:400 Dako, Carpinteria, CA, USA
Calponin 1:200 Dako, Carpinteria, CA, USA
GFAP 1:8500 Novocastra, Newcastle, UK
P63 1:200 Dako, Carpinteria, CA, USA
Ki67 1:100 Dako, Carpinteria, CA, USA
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Using the Kaplan-Meier survival curve, the overall survi-
val rates of 16 patients with MEC at 3 years and 5 years
were 68% and 45%, respectively (Figure 1).
The relationship between immunohistochemical findings
and follow-up
Of the 16 cases, 15 were immunohistochemically posi-
tive for vimentin and calponin staining (93.8%). S-100
protein was immunoreactive in 13 tumours (81.3%)
(Figure 2A), immunoreactivity for SMA was seen in 6
cases (37.5%), CK14 reactivity was noted in 12 tumours
(75.0%), and GFAP showed positivity in 7 cases (43.8%)
(Figure 2B). In addition, limited staining for desmin was
observed in 2 cases (12.5%). Using the c
2 test, no statis-
tically significant correlation was demonstrated between
the clinical outcomes (recurrence, metastasis, and survi-
val) and these markers.
Immunohistochemical findings for the expression of p63
showed nuclear staining for p63 in 6/16 (37.5%) cases
(Figure 2C; Table 2). The mean age of the four p63-posi-
tive EMC cases was 61.0 years as compared with 38.2
years for the p63-negative EMCs. All six patients with
p63-positive expression had recurrence. A statistically sig-
nificant correlation was found between p63 expression
and the recurrence of EMC (P = 0.01). Four patients with
p63-positive expression had metastasis and two patients
with p63-negative expression had no metastasis. p63
expression showed a statistically significant correlation
with metastasis (P = 0.03). All six patients with p63-posi-
tive expression died due to disease or cardiovascular dis-
ease (mean survival time = 50.5 months). P63 expression
yielded a statistically significant difference with respect to
survival (P = 0.01) (c
2 = 6.49, p = 0.01, Figure 3).
Nuclear Ki-67 expression was observed in 5/16
(31.3%) cases (Table 2, Figure 2D). The mean age for
Ki-67-positive EMCs was 64.8 years as compared with
42.5 years for Ki-67-negative EMCs. A statistically sig-
nificant correlation was found between Ki-67 expression
and recurrence of EMC (P = 0.03). Ki-67 expression
showed a statistically significant correlation with metas-
tasis (P = 0.01). Four patients with Ki-67-positive
expression died due to disease or cardiovascular disease
(mean survival time = 44.0 months). There was no sta-
tistically significant difference between Ki-67 expression
and survival (c
2 = 1.38, P = 0.24) (Figure 4).
Discussion
Myoepithelial carcinoma (MEC) is rare, and the causes,
clinical behaviour, diagnostic criteria, and outcomes are
Table 2 p63 and Ki67 Expression, Clinicopathologic Features and Outcome in 14 MECs
Case Age/
sex
Site Treatment Recurrence Metastasis Follow-up, month
(after first time treatment)
P63 Ki67
1 45/M Nasal septum Surgery+ postoperative RT No No NED(46 months) - -
2 51/M L Maxillary sinus Preoperative RT+ Surgery+
postoperative RT+CT
Yes, 17
months
Yes, 20 months,
lung
Dead due to MD(23 months) + -
3 80/F L Parotid gland Surgery Yes, 12
months
No Dead due to cardiovascular
disease (34 months)
++
4 26/F R Parotid gland Surgery+ postoperative RT No No NED(27 months) - -
5 68/M R Parotid gland Surgery+ postoperative RT Yes, 32
months
Yes, 40 months,
lung
Dead due to MD(72 months) + +
6 22/M R submandibular
gland
Surgery No No NED(33 months) - -
7 62/M Larynx Surgery+ postoperative RT Yes, 38
months
Yes, 32 months,
liver
Dead due to MD(39 months) + +
8 40/F L Maxillary sinus Surgery+ postoperative RT+CT Yes, 9
months
No DOD(13 months) + ¯
9 58/M L lung Surgery+ postoperative RT+CT Yes, 1
months
No Alive with tumor (32 months) - -
10 49/M Nasal septum Surgery+ postoperative RT No No NED(12 months) - -
11 39/M L breast Surgery No No NED(36 months) - -
12 65/F R breast Surgery Yes,10
months
Yes, 32 months,
lung
DOD (35 months) + +
13 44/M Palate Surgery+ postoperative RT Yes,16
months
No NED(52 months) - -
14 49/M L lung Surgery+ postoperative RT+CT Yes,21
months
Yes, 37 months,
brain
Dead of due to MD (40 months) - +
15 53/M L lung Surgery+ postoperative RT+CT No No NED(34 months) - -
16 38/F L Parotid gland Surgery+ postoperative RT No No NED(54 months) - -
Abbreviations: RT radiotherapy, CT chemotherapy, L left, R right, MD metastatic disease, DOD die of disease
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ing benign lesions, such as pleomorphic adenomas and
benign myoepitheliomas
2, but can also arise de novo [1,5].
The precise pathologic definition of MEC remains a
matter of controversy because of the morphologic varia-
tions in neoplastic myoepithelial cells. Immunohisto-
chemistry is useful for confirming myoepithelial
differentiation in MEC, such that all tumours are posi-
tive for at least one epithelial marker, cytokeratin or
EMA, and most also express either S100 or GFAP
[2,7,22]. In the current series, the myoepithelial markers
p63 and CK14 were positive in 37.5% and 75.0% of the
cases, respectively. The most sensitive myogenic markers
were vimentin and calponin (positive in 93.8% of our
cases), but these antibodies have little specificity, as they
are also expressed in tumours showing smooth muscle
or myofibroblastic differentiation [22]. We found nearly
all MECs were positive for S-100 protein (81.3%),
whereas nearly half were immunoreactive for GFAP
(46%), a reactivity profile similar to previously reported
result [2]. It has been suggested that assessing cell
Figure 1 Using the Kaplan-Meier survival curve, the overall
survival rates of 16 patients with MEC at 3 years and 5 years
were 68% and 45%, respectively (c
2 = 6.49, p = 0.01).
Figure 2 Immunohistochemical analysis showed that expression of S-100 protein (A), GFAP (B), p63 (C) and Ki67 (D) were positive.
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diagnosis of MEC, and that a Ki-67 labelling index of
more than 10% is diagnostic of MEC [2,4]. In the pre-
sent series, Ki-67 was observed in 5/16 (31.3%) cases.
While none of these antibodies are specific for myoe-
pithelial cells, the combination of positive findings sup-
port the diagnosis of tumours originating from
myoepithelial differentiation [2,4,7,22].
I nt h ep r e s e n ts t u d y ,t h em o s tc o m m o ns i t eo fM E C s
was the minor salivary gland (7 cases), whereas the
major salivary gland was affected in 4 cases. Recurrence
and metastasis rates were high (56.3% and 31.3% of
cases, respectively). The sites of metastases included the
lung, liver, and brain. Seven patients died of their dis-
ease at last follow-up and one patient died due to cardi-
ovascular disease. In this study, we analysed the
relationship between these markers with clinical out-
comes. There were no statistically significant correla-
tions between the clinical outcomes (recurrence,
metastasis, and survival) and several markers (vimentin,
calponin, S-100, SMA, CK14, GFAP, and desmin).
Although our study included a small number of cases,
the results indicated that p63 overexpression is predictive
of an unfavourable course. EMCs positive for p63 were
diagnosed in older patients (mean age 61.0 years) and
p63-negative EMCs were associated with younger
patients (mean age 38.2 years). Compared with p63-nega-
tive EMCs patients, patients with p63-positive EMCs
were showed recurrence, distant metastasis, and poor
prognosis (p < 0.05). To our knowledge, no reported
study has investigated the correlation between p63
expression and outcomes of MECs. Our results were
similar to other reports describing different malignant
tumours [10-13]. Lo Muzio et al. found that oral squa-
mous cell carcinoma (SCC) patients with p63 overexpres-
sion had a poorer survival rate compared to oral SCC
patients with a normal pattern of expression (P =0 . 0 2 4 ) .
They also suggested that the p63 expression patterns
were a reliable indicator of histological grading and an
early marker of poor prognosis [11]. Ramer et al. revealed
that overexpression of p63 was an independent prognos-
tic factor of adenoid cystic carcinoma of the salivary
gland, as determined by multivariate analysis using the
Cox proportional hazard model (p = 0.012) [12]. Asioli
also found p63 overexpression to be a strong indepen-
dent prognostic factor (P < 0.001) in Merkel cell carci-
noma, as indicated by multivariate Cox regression
analysis [13]. p63 expression has been suggested to have
an oncogenic role in the cell proliferation changes
observed during carcinogenesis [23]. Conversely, Tuna et
al. found that lower p63 expression was correlated with
tumour stage, grade, and survival time of urothelial carci-
noma (UC) patients (p < 0.05) [9]. They suggested that
p63 reactivity appeared to be a useful prognostic factor in
UC cases [9]. In esophageal squamous cell carcinoma
patients, Takahashi et al. revealed that p63-negative
expression was associated with poor prognosis and
tended to correlate with distant metastasis (p = 0.06), and
was not an independent prognostic factor for overall sur-
vival, as assessed using multivariate analysis (p =0 . 6 9 )
[10]. Therefore, whether p63 expression contributes to
prognostic value of these tumours requires further study.
Figure 3 P63 expression yielded a statistically significant
difference with survival (c
2 = 6.49, p = 0.01).
Figure 4 There was not a statistically significant difference
between Ki67 expression and survival (c
2 = 1.38, P = 0.24).
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the proliferative stage of tumour cells than proliferating-
cell nuclear antigens (PCNA), and Ki-67 immunoreactiv-
ity has been reported to correlate with the prognosis of
many cancers [15-20]. In laryngeal carcinoma patients,
Ashraf et al. found that tumoural Ki-67 expression corre-
lated significantly with tumour grade (P =0 . 0 1 7 )a n d
mitotic count (P = 0.001). They suggested that Ki-67
expression in tumoural tissue may be a prognostic mar-
ker in patients with laryngeal SCC [15]. Tang et al.
revealed Ki-67 expression was an independent prognostic
factors of overall survival in salivary adenoid cystic carci-
noma, as assesses using multivariate Cox’sp r o p o r t i o n a l
hazards analysis [16]. In hepatocellular carcinoma
patients, Ki-67 was also found to be a significant inde-
pendent predictor of survival [18]. However, we did not
demonstrate the prognostic value of Ki-67 in MECs in
the present study. There was no statistically significant
difference between Ki-67 expression and survival (P =
0.24). However, our results showed that Ki-67 overex-
pression is related to recurrence and metastasis of MECs.
Our study results are in accordance with Li et al. who
found that Ki-67 was correlated with lymph node metas-
tasis and was not correlated with prognosis [24]. Our
results support the model of carcinogenesis, with
increased loss of control of cellular proliferation with the
accumulation of genetic alterations in dysplastic lesions.
Conclusions
To our knowledge, the present study is the first to
report the prognostic significance of p63 and Ki-67 in
MECs. Despite the small number of cases in the present
study, the data suggest that recurrence and metastasis in
EMCs are more frequent in p63-positive and Ki-67-posi-
tive EMCs, and poor prognosis is associated with over-
expression of p63. However, the associations between
recurrence, metastasis, and prognosis and the expression
of p63 and Ki-67 require further evaluation in a larger
series of patients to validate these findings.
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